stocktrademan
9 years ago
$HOLX recent news/filings
bullish
## source: finance.yahoo.com
Sat, 20 Jun 2015 05:18:00 GMT ~ 1:18 am Hologic prices $1.0 bln of 5.250% Senior Notes due 2022
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#holx
*********************************************************
Fri, 19 Jun 2015 10:02:49 GMT ~ HOLOGIC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150619/holx8-k.html
*********************************************************
Fri, 19 Jun 2015 00:33:05 GMT ~ Hologic Announces Pricing of Offering of $1.0 Billion Aggregate Principal Amount of 5.250% Senior Notes Due 2022
[at noodls] - BEDFORD, Mass. , June 18, 2015 /PRNewswire / -- Hologic, Inc. (NASDAQ: HOLX) announced today that it has priced its previously announced private offering of $1.0 billion aggregate principal amount of 5.250% ...
read full: http://www.noodls.com/view/9D7B62CB2023037264197B9D58377B429E00C166
*********************************************************
Fri, 19 Jun 2015 00:12:00 GMT ~ Hologic Announces Pricing of Offering of $1.0 Billion Aggregate Principal Amount of 5.250% Senior Notes Due 2022
[PR Newswire] - BEDFORD, Mass., June 18, 2015 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that it has priced its previously announced private offering of $1.0 billion aggregate principal amount of 5.250% senior notes due 2022 at an issue price of $1,000 per $1,000. The 2022 notes will be unsecured obligations of the Company and will be guaranteed by certain of its direct and indirect subsidiaries. Hologic intends to use the net proceeds of the offering, plus available cash, to redeem its outstanding 6.25% senior notes due 2020 in the aggregate principal amount of $1.0 billion.
read full: http://finance.yahoo.com/news/hologic-announces-pricing-offering-1-001200054.html
*********************************************************
Thu, 18 Jun 2015 14:56:03 GMT ~ Hologic, Inc. -- Moody's assigns B1 to Hologic's new bond
read full: http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_328021&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20150618_PR_328021
*********************************************************
$HOLX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$HOLX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/HOLX/company-info
Ticker: $HOLX
OTC Market Place: Not Available
CIK code: 0000859737
Company name: Hologic, Inc.
Incorporated In: DE, USA
$HOLX share structure
## source: otcmarkets.com
Market Value: $10,749,911,664 a/o Jun 19, 2015
Shares Outstanding: 280,969,986 a/o Apr 24, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$HOLX extra dd links
Company name: Hologic, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=HOLX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=HOLX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=HOLX+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/news - http://finance.yahoo.com/q/h?s=HOLX+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/HOLX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=HOLX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/HOLX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Hologic%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Hologic%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Hologic%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/HOLX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000859737&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=HOLX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=HOLX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=HOLX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=HOLX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=HOLX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=HOLX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=HOLX+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/HOLX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=HOLX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/HOLX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=HOLX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/HOLX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/HOLX/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/HOLX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/HOLX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/HOLX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=HOLX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HOLX
$HOLX DD Notes ~ http://www.ddnotesmaker.com/HOLX
surf1944
11 years ago
8:05AM Hologic: Breast Brachytherapy Registry Trial Final Results; MammoSite APBI Demonstrates 'Excellent' Cosmesis and Low Local Recurrence (HOLX) 20.84 : Co announces that the final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial data confirms previously noted "excellent" results and compares favorably with other forms of accelerated partial breast irradiation and with outcomes seen in patients treated with whole breast irradiation with similar follow-up. "With over 1,400 patients treated and follow-up exceeding five years, it is the only brachytherapy study with over 1,000 patients accrued and five year follow-up available at this time. The final analysis of this trial not only confirmed the efficacy of brachytherapy based partial breast irradiation, but demonstrated that rates of toxicity following treatment remain low and favorable, in line with previously reported toxicity rates using whole breast irradiation."
mlkrborn
13 years ago
Good earnings & Buying a compay @ $82 a share! $19 NOW!
Hologic reports EPS in-line, revs in-line; guides Q3 EPS slightly below consensus, revs below consensus; reaffirms FY12 revs guidance; reaffirms FY13 EPS guidance; to acquire GPRO in an accretive transaction (see 6:33) (HOLX) 21.23 : Reports Q2 (Mar) earnings of $0.33 per share, excluding non-recurring items, in-line with the Capital IQ Consensus Estimate consensus of $0.33; revenues rose 7.4% year/year to $471.2 mln vs the $473.83 mln consensus. Co issues slight downside guidance for Q3, sees EPS of ~$0.34 vs. $0.35 Capital IQ Consensus Estimate; sees Q3 revs of $475-480 mln, excluding non-recurring items, vs. $482.29 mln Capital IQ Consensus Estimate. Co reaffirms guidance for FY12, sees FY12 revs of $1.9-$1.925 bln vs. $1.92 bln Capital IQ Consensus Estimate. Co reaffirms guidance for FY13, sees EPS of $1.36-1.38, excluding non-recurring items, vs. $1.52 Capital IQ Consensus Estimate. Co may not generate expected revenues and may incur expenses or charges or realize income or gains in fiscal 2012 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and its filings with the Securities and Exchange Commission, could adversely affect anticipated results. "We are once again very pleased we experienced year-over-year revenue growth in all four of our business segments and our operating results were in-line with expectations, given the second quarter is historically our slowest as a result of resetting deductibles and the timing of orders for capital equipment."
6:33AM Gen-Probe to be acquired by Hologic (HOLX) for $82.75/share in cash; HOLX expects transaction to be $0.20 accretive to adjusted EPS in first fiscal year after close (GPRO) 68.70 : Cos announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic (HOLX) will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of ~ $3.7 bln. The all-cash transaction is expected to be funded through available cash and additional financing of term loans and high yield securities. The transaction is expected to be completed in the second half of calendar 2012. The transaction is expected to be $0.20 accretive to Hologic's adjusted earnings per share in the first fiscal year after close and significantly more accretive thereafter. Hologic also expects the transaction to accelerate top and bottom line growth rates. The combined company expects to realize approximately $75 million in cost synergies within three years following the close of the transaction. In addition, the combined company expects to have strong free cash flows, which will be used primarily to reduce debt with the expectation to return to pre-transaction leverage levels within three years.